J.S.D., Columbia University School of Law
LL.M., Columbia University School of Law
LL.B. and undergraduate diploma in biology, magna cum laude, Tel Aviv University
Yaniv Heled’s research focuses on legal and ethical aspects of biomedical technologies. He has written on such topics as the regulation of biologics and biosimilars, stem cells, human reproductive tissue, DNA sequencing and testing, and more. His recent notable scholarship includes the article, “Follow-On Biologics Are Set Up to Fail,” which explains why there is not going to be meaningful competition in biologics under current market and regulatory conditions. In another article, “Why Healthcare Companies Should (Be)come Benefit Corporations,” Heled and co-authors, Liza Vertinsky and Cass Brewer, make the case for requiring companies involved in the provision of healthcare products and services to incorporate (or re-incorporate) as benefit corporations, a relatively new type of business entity which is required to consider not only corporate profits but also public health.
Heled is on the faculty of Georgia State University’s Center for Law, Health & Society and is the Co-Director of the Georgia State University Center for Intellectual Property Law. He teaches the courses: Patent Law, Family Law, Law & Biotechnology, Policy & Ethics, and Different & Unusual Forms of Intellectual Property.
Prior to joining Georgia State Law, Heled practiced intellectual property law with Goodwin Procter LLP in New York.
Heled earned a J.S.D. from Columbia University School of Law. His doctoral dissertation focused on the regulation of novel biomedical technologies. In addition, Heled holds an LL.M. from Columbia, where he was a Harlan Fiske Stone Scholar, and an LL.B. and undergraduate Diploma in Biology, magna cum laude, from Tel Aviv University.